Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q3 2024 Earnings Presentation
15 slides from Sanara Medtech's earnings presentation, Nov 13, 2024
Slide 1: Q3 2024 Earnings and Business Update Call
Q3 2024 Earnings and Business Update Call November 13, 2024
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Executive Summary
Executive Summary • Financial Update (Unaudited) • Highest net revenue quarter in the Company’s history ($21.7 million) • Twelfth consecutive record net revenue quarter • Net loss of $2.9 million in Q3 • Adjusted EBITDA(1) of $0.8 million in Q3 • Core Surgical Business (Excluding THP) • Segment net
Slide 4: Surgical Sales
Surgical Sales Sales Overview (Unaudited) • Sanara products were sold in over 1,200 hospitals across 34 states plus the District of Columbia, based on a minimum of $50,000 revenue, during the TTM period ended September 30, 2024. • Sanara products were contracted or approved to be sold in more than 4
Slide 5: Surgical Growth Opportunities
Surgical Growth Opportunities Additional Facility Approvals • Recently executed a contract with a national GPO giving SMTI sales team access to an additional 1,000+ facilities. • Team is working to further penetrate existing facilities while also generating sales in new facilities. Additional Specia
Slide 6: Tissue Health Plus
Tissue Health Plus 6
Slide 7: Q3 focused on team building and platform execution
Q3 focused on team building and platform execution Planned THP Model THP Golden Triangle Progress o Rapid on-boarding of a global team across clinical, commercial, platform & administrative functions Connected Payor o Standard of care expanded to include atypical wounds marking a first in the indust
Slide 8: Financial Highlights
Financial Highlights 8
Slide 9: Q3 2024 Financial Highlights (Unaudited)
Q3 2024 Financial Highlights (Unaudited) • Revenue • For the three months ended September 30, 2024, Sanara generated net revenue of $21.7 million compared to net revenue of $16.0 million for the three months ended September 30, 2023, a 35% increase from the prior year period. • The higher net revenu
Slide 10: Q3 2024 Financial Highlights (Continued)
Q3 2024 Financial Highlights (Continued) • Depreciation, Amortization and Interest Expense • Depreciation and amortization expenses for the three months ended September 30, 2024 were $1.1 million compared to $1.0 million for the same period in 2023. The higher depreciation and amortization expenses
Slide 11: Segment Reporting
Segment Reporting • Segment Reporting Overview • Break out of Tissue Health Plus and Sanara Surgical demonstrates our strategic rationale of the acute/post acute comprehensive strategy investments. Three Months Ended September 30, 2024 Three Months Ended September 30, 2023 Surgical THP Total Surgica
Slide 12: Questions
2 Questions « Sanara MedTech Evidence Based Healing
Slide 13: Appendix
Appendix . Sanara * MedTech Evidence Based Healing
Slide 14: Non-GAAP Financial Measures
Non-GAAP Financial Measures Use of Non-GAAP Financial Measure To supplement the Company’s financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this press release and on the related
Slide 15: Reconciliation of GAAP to Non-GAAP Financial Measures (Consolidated)
Reconciliation of GAAP to Non-GAAP Financial Measures (Consolidated) Three Months Ended September 30, 2024 2023 Sanara Sanara Surgical THP Total Surgical THP Total Net Income (Loss) $ (180,488) $(2,702,564) $(2,883,052) $ 567,235 $(1,662,184) $(1,094,949) Adjustments: Interest expense 927,577 - 927,